CURRENT STATUS
The eye is the leading proving ground for gene therapy: Luxturna (voretigene neparvovec) became the first FDA-approved in-vivo gene therapy for a genetic disease, restoring vision in RPE65-mediated inherited retinal disease. Approved complement therapies (Syfovre, Izervay) now slow geographic-atrophy AMD, while single-injection gene therapies (RGX-314, ADVM-022) aim to replace the monthly anti-VEGF burden. Optogenetics and stem-cell RPE replacement are in early trials, and cortical visual prostheses aim to bypass the eye entirely.
KEY BREAKTHROUGHS
Luxturna (voretigene neparvovec): gene therapy restoring vision in RPE65 blindness, approved 2017
Editas EDIT-101: first in vivo CRISPR therapy for Leber congenital amaurosis type 10
GenSight optogenetics: partially restoring vision in blind RP patients using channelrhodopsin
Google DeepMind AI detecting 50+ eye diseases from OCT scans with expert-level accuracy
SI-COMPRESSED PIPELINE
SI TOOLS ACCELERATING CURES
KEY ORGANIZATIONS
KEY CLINICAL TRIALS
RESTORE: MCO-010 Optogenetic Therapy for Retinitis Pigmentosa (Phase 2b/3)
ViewNanoscope Therapeutics
A mutation-agnostic optogenetic therapy delivered by a single intravitreal injection that makes surviving retinal cells light-sensitive, restoring vision regardless of the underlying gene defect. Met its primary endpoint with durable visual-acuity gains through 3 years; FDA BLA submission underway.
LUMEOS: Botaretigene Sparoparvovec for X-Linked RP (Phase 3)
ViewJohnson & Johnson / MeiraGTx
A one-time subretinal gene therapy delivering functional RPGR to the retina in X-linked retinitis pigmentosa. The Phase 3 trial narrowly missed its primary mobility endpoint in 2025, though subsets improved on low-luminance acuity and perimetry, informing next-generation trial design.
TIMELINE ESTIMATE
Inherited retinal blindness: treatable now. AMD gene therapy: 3β5 years. Full restoration (brain interfaces): 8β12 years.